Seeking Alpha HealthcareOriginal article
AbbVie's ABBV-295 delivers up to 9.8% weight loss in Phase 1
Phase 1positiveABBV-295Positive
AI Analysis
Summary
AbbVie's ABBV-295 demonstrated weight loss of up to 9.8% in Phase 1 testing, showing early promise for the obesity indication.
Clinical Trial Data
Phase
1
Primary Endpoint
Met
Outcome Details
up to 9.8% weight loss
Importance:5/10
Sentiment:
0.70
obesityweight-lossPhase 1clinical trial
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on September 30, 2026 10:04 AM